Navigation Links
Staying One Step Ahead of Osteoporosis
Date:2/26/2009

oblem in other parts of the world. In another study, Leonid Kandel, MD, an orthopaedic surgeon at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, looked at improving the diagnosis rate of osteoporosis in post menopausal women, who fracture the distal radius bone, which is located in the lower arm, near the wrist. Dr. Kandel says these fractures are often the first clinical symptom of osteoporosis, yet only 15 to 25 percent of these women are referred for a bone density test by a family physician after the fracture.

"It is important that patients understand the connection between their current problem, the fracture, and the possibility that the underlying cause is osteoporosis." Dr. Kandel also suggests that there should be a stronger connection and better communication between the hospital and the community. He feels this will increase the number of patients who are diagnosed and treated for the disease. Osteoporosis in Women after Distal Radius Fracture Study 475 (http://www3.aaos.org/education/anmeet/anmt2009/podium/podium.cfm?Pevent=475)

Francesco Pegreffi, MD, an orthopaedic surgeon in the Department of Shoulder and Elbow Surgery at Cervesi Hospital, Cattolica, Italy, along with Lorena Belletti, MD, and Professor Maria Teresa Mascia, in the Department of Rheumatology, University of Modena, Italy, studied a group of patients, 80 percent women and 20 percent men, who were affected by rheumatoid arthritis and under Vitamin D supplementation. "We wanted to analyze the correlation between a person's age, sex, how long they had rheumatoid arthritis, whether they were taking Vitamin D supplements and whether they had fragility fractures due to osteoporosis," said Dr. Pegreffi.

"We f
'/>"/>

SOURCE American Academy of Orthopaedic Surgeons
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Patient Enrollment in Urgent(R) PC SUmiT Clinical Trial Completed Ahead of Schedule
2. Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies
3. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
6. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
7. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
8. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
9. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
10. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
11. Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...
(Date:12/16/2009)... Dec. 16 Naurex Inc., a new ... and other CNS disorders based on its novel ... presented at a major medical meeting showed that ... anxiolytic-like activity with no signs of the CNS-related ... NMDA receptor(1). The studies also showed that ...
(Date:12/16/2009)... NEW YORK, Dec. 16 Keryx ... today the initiation of a Phase 3 ... Company,s PI3K/Akt pathway inhibitor, in relapsed / ... entitled, "A Phase 3 Randomized Study to ... Added to the Combination of Bortezomib (Velcade®) ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7New Directions in Angioedema 3A A Focus on Etiologies and Clinical Approach 48496 1New Directions in Angioedema 3A A Focus on Etiologies and Clinical Approach 48496 2Parents key in new measure to evaluate language in children with autism 48494 1Parents key in new measure to evaluate language in children with autism 48494 2Parents key in new measure to evaluate language in children with autism 48494 3Pre pregnancy depressed mood may heighten risk for premature birth 8792 1Pre pregnancy depressed mood may heighten risk for premature birth 8792 2Pre pregnancy depressed mood may heighten risk for premature birth 8792 3
... ARIAD,Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical,investigators ... and,1b clinical data from ongoing trials of the ... of the American Society,of Clinical Oncology (ASCO) in ... from the Phase 2 trial of single-agent,AP23573 in ...
... /PRNewswire-FirstCall/ -- Iomai,Corporation today announced that it will ... patch-based needle-free influenza vaccine,before the markets open tomorrow. ... at 8:30 a.m. Eastern Time tomorrow to discuss,the ... the live conference call Friday, May 25, 2007 ...
Other Medicine Technology:Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 2Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 3Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 4Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2
(Date:12/16/2009)... Quantros, Inc., a leading provider of safety and ... healthcare industry, announces the creation of a new ... industry veteran Michael Tulloch, MBA, as Director of ... company,s new Marlborough, MA office. ,, "The expansion ... Tulloch. "Quantros has been developing software for the ...
(Date:12/16/2009)... What happens when the families of sick and dying ... or for them? How do pediatricians respond to such ... religion and spirituality help some patients and families cope ... is almost always the families and patients who raise ... In the current issue of Southern Medical Journal ...
(Date:12/16/2009)... Dec. 16 Tyco International Ltd. (NYSE: ... of Michael E. Daniels for election to the ... General Meeting on March 10, 2010. ,, ... Global Technology Services group of International Business Machines ... for IBM,s Global Services business operations consisting of ...
(Date:12/16/2009)... While many of the,pharma companies are struggling ... and inmarket drugs, MarketsandMarkets on the other ... players. These pharma,forecasting solutions are designed for ... phase,III. These have a substantial impact on ... strategy, manufacturing planning, sales force,promotion, and planning. ...
(Date:12/16/2009)... donates time and money to help clothe children in need. ... ... Florida dry cleaner Dryclean USA Florida , along with Atlantic ... Hope to help clothe children in need by collecting funds ... will begin distributing cards, with delivery of their clean clothes, and ...
Breaking Medicine News(10 mins):Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Prayer on the hospital floor 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:Pay a Dollar, Dress a Child: Helping Struggling Families with Small Donations 2
... Internet - , , ANTHEM, Ariz., Dec. 29 ... of its new web site at http://www.mychoicedentist.com and ... Phoenix , Arizona, area is proceeding successfully. "Arizona is ... CEO. "We anticipate expanding this service to almost every major ...
... Now Worth Twenty-Five Thousand Dollars at www.MaxMuscle.com/max-formation/ , ... ... Sports Nutrition is rewarding $25,000 cash to the individual who can ... lean muscle and fitness in 2009., , , , ,Bring Yourself ...
... Critically ill patients frequently have uncertain prognoses, but ... prognostic uncertainty candidly, according to a new study ... Center. , "Our interviews revealed that caregivers ... and just the nature of life," said lead ...
... a timely reminder of the issues surrounding the binge ... people and alcohol, a team lead by Professor Christine ... funded by the Economic and Social Research Council (ESRC) ... Focusing on the role of marketing practices in shaping ...
... Team Sponsored by Land Rover, St. Regis Resort Aspen, National ... Land Rover America,s Polo Cup Team participated in the prestigious ... weekend filled with world class polo and camaraderie on and ... was comprised of John Gobin at 8 goals, (one of ...
... against troublesome complication, study finds , , FRIDAY, Dec. 26 ... before cardiac surgery may lower their chances of having ... on variables such as age and the complexity of ... this condition of confusion following heart surgery. The condition ...
Other Medicine News:Health News:Prime Companies Announces Launch of New Dental Web Site 2Health News:Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution 2Health News:Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution 3Health News:Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution 4Health News:Family members of critically ill patients want to discuss loved ones' uncertain prognoses 2Health News:T'is the season to be jolly? 2Health News:Land Rover America's Polo Cup Team Plays in USPA World Snow Polo Championships, Aspen, Colorado 2Health News:Land Rover America's Polo Cup Team Plays in USPA World Snow Polo Championships, Aspen, Colorado 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: